首页>
外国专利>
METHOD FOR PREDICTION OF CLINICAL COURSE IN PATIENTS WITH BRAIN METASTASES
METHOD FOR PREDICTION OF CLINICAL COURSE IN PATIENTS WITH BRAIN METASTASES
展开▼
机译：预测患有脑转移的患者的临床课程的方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to neurooncology, and can be used to determine the survival rate of the patients with brain metastases. Preoperative MRI examination is performed with scanning protocol with diffuse-weighted images (DWI). A parametric map of the measured diffusion coefficient (MDC) in the area of metastasis is constructed. Kaplan-Meier curves are used to determine the patient's life span. Additionally, the degree of proliferative tumor activity (Ki-67) is determined by the MDC values taking into account the results of retrospective MRI with MDC construction and histologic studies with determination of Ki-67 in the patients previously operated on for cerebral metastases, and information on the length of their life. With MDC≥947.2 mm2/s, proliferative activity index Ki-67≤29 %, median survival is 9.8 months (8.6–11.3 months). With MDC947.2 mm2/s, proliferation activity index Ki-6729 %, median survival being 6.4 months (3.7–9.1 months).;EFFECT: method is low traumatic and provides higher reliability of determining the patient's survival rate with brain metastases by taking into account the Ki-67 tumor proliferative potential factor, which is an important prognostic factor, from the MDC values.;1 cl, 4 dwg, 2 tbl, 2 ex
展开▼
机译：技术领域本发明涉及医学，即神经肿瘤学，可用于确定脑转移患者的存活率。术前MRI检查是采用弥散加权图像（DWI）的扫描协议进行的。构造转移区域中测得的扩散系数（MDC）的参数图。 Kaplan-Meier曲线用于确定患者的寿命。此外，增生性肿瘤活性（Ki-67）的程度由MDC值决定，同时考虑了先前行脑转移手术的患者的回顾性MRI与MDC构建和组织学研究的结果，并确定了Ki-67。有关其寿命的信息。 MDC≥947.2mm 2 / s，增殖活性指数Ki-67≤29％，中位生存期为9.8个月（8.6-11.3个月）。当MDC <947.2 mm 2 / s时，增殖活性指数Ki-67> 29％，中位生存期为6.4个月（3.7-9.1个月）.;效果：该方法创伤小且可靠性更高通过从MDC值考虑到重要的预后因素Ki-67肿瘤增殖潜能因素，确定患者发生脑转移的存活率。1cl，4 dwg，2 tbl，2 ex
展开▼
